ALDX
Aldeyra Therapeutics, Inc. NASDAQ Listed May 2, 2014$1.83
After hrs
$1.83
+0.00%
Mkt Cap $110.4M
52w Low $1.07
14.9% of range
52w High $6.17
50d MA $1.71
200d MA $3.90
P/E (TTM)
—
EV/EBITDA
—
P/B
2.5x
Debt/Equity
0.3x
ROE
-76.5%
P/FCF
0.0x
RSI (14)
52.20
ATR (14)
$0.15
Beta
1.33
50d MA
$1.71
200d MA
$3.90
Avg Volume
1.2M
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
131 Hartwell Avenue · Lexington, MA 02421 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.14 | -0.11 | +21.4% | 5.46 | -1.1% | +2.9% | -9.1% | +1.8% | -10.6% | +3.2% | — |
| Nov 5, 2025 | AMC | -0.17 | -0.13 | +23.5% | 4.93 | +0.2% | -2.4% | -2.5% | +9.4% | +1.9% | +1.3% | — |
| Aug 7, 2025 | AMC | -0.21 | -0.16 | +23.8% | 5.17 | -0.2% | +1.7% | -0.2% | +2.1% | +0.2% | -1.3% | — |
| May 14, 2025 | AMC | -0.25 | -0.17 | +32.0% | 2.17 | +0.9% | -0.5% | +0.0% | +12.0% | -2.5% | -4.7% | — |
| Feb 28, 2025 | AMC | -0.25 | -0.27 | -8.0% | 5.11 | +2.5% | +18.6% | +1.8% | -0.3% | +2.3% | +1.0% | — |
| Nov 7, 2024 | AMC | -0.25 | -0.25 | +0.0% | 5.34 | +0.6% | +3.4% | -0.5% | -13.3% | -7.4% | -3.2% | — |
| Aug 1, 2024 | AMC | -0.14 | -0.28 | -100.0% | 3.71 | -5.9% | -5.1% | -8.2% | +6.5% | -5.2% | +28.5% | — |
| May 2, 2024 | AMC | -0.08 | -0.14 | -75.0% | 4.21 | +0.5% | -1.2% | -1.0% | +1.2% | -2.4% | -3.2% | — |
| Mar 7, 2024 | AMC | -0.21 | -0.08 | +61.9% | 3.85 | -1.8% | -6.0% | -10.2% | -7.4% | -3.7% | -4.5% | — |
| Nov 3, 2023 | AMC | -0.24 | -0.14 | +41.7% | 2.21 | +0.4% | +1.8% | +23.1% | -5.8% | -9.8% | -3.0% | — |
| Aug 3, 2023 | AMC | -0.31 | -0.15 | +51.6% | 7.92 | +2.0% | +1.4% | -6.2% | -1.2% | +1.9% | +0.5% | — |
| May 4, 2023 | AMC | -0.30 | -0.27 | +10.0% | 10.39 | +0.7% | +1.7% | +0.9% | -3.8% | -0.3% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.24 | $1.20 | -3.2% | +14.5% | +28.9% | -1.1% | +23.2% | -16.1% |
| Nov 10 | BTIG | Maintains | Buy → Buy | — | $4.69 | $4.74 | +1.1% | +9.4% | +1.9% | +1.3% | -5.3% | +0.6% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.15 | -0.5% | +12.0% | -2.5% | -4.7% | +0.0% | -1.3% |
| Apr 7 | BTIG | Maintains | Buy → Buy | — | $1.89 | $1.80 | -4.8% | +3.2% | -1.5% | +1.0% | -2.6% | +1.1% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.40 | -1.4% | +33.1% | +3.2% | -1.5% | +1.0% | -2.6% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.11 | $5.24 | +2.5% | +18.6% | +1.8% | -0.3% | +2.3% | +1.0% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.19 | $4.19 | +0.0% | +21.7% | -6.9% | -0.8% | -0.4% | +11.9% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.71 | $3.49 | -5.9% | -5.1% | -8.2% | +6.5% | -5.2% | +28.5% |
| May 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.16 | $4.16 | +0.0% | -1.0% | +1.2% | -2.4% | -3.2% | -4.3% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.16 | +0.0% | -1.0% | +1.2% | -2.4% | -3.2% | -4.3% |
| Apr 3 | Oppenheimer | Upgrade | Perform → Outperform | — | $3.55 | $3.65 | +2.8% | +16.9% | +12.8% | +0.9% | -7.2% | +1.1% |
| Oct 17 | Oppenheimer | Downgrade | Outperform → Perform | — | $1.83 | $1.80 | -1.6% | +0.5% | -6.0% | -4.0% | -0.6% | -9.7% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $1.83 | $1.80 | -1.6% | +0.5% | -6.0% | -4.0% | -0.6% | -9.7% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.44 | $7.43 | -0.1% | +1.9% | +0.5% | +0.9% | -0.3% | +2.5% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $8.06 | +2.0% | +6.2% | -4.9% | -1.9% | -0.9% | -0.6% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.72 | $7.90 | +2.3% | +0.4% | -8.3% | +5.6% | -0.7% | +3.6% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.87 | $10.96 | +0.8% | -3.2% | +1.1% | -27.4% | +0.4% | -8.3% |
| Jun 1 | Citigroup | Maintains | Buy → Buy | — | $9.49 | $9.45 | -0.4% | +9.3% | +2.7% | +6.6% | -0.4% | +1.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.39 | $10.46 | +0.7% | +1.7% | +0.9% | -3.8% | -0.3% | +1.2% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $7.90 | $8.00 | +1.3% | -9.1% | -2.2% | +12.0% | -0.6% | +1.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $8.00 | +1.3% | -9.1% | -2.2% | +12.0% | -0.6% | +1.9% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.76 | $6.80 | +0.6% | +4.9% | +5.8% | -0.3% | -1.6% | -2.0% |
| Nov 21 | Citigroup | Maintains | Buy → Buy | — | $5.19 | $5.19 | +0.0% | -0.6% | +2.7% | +1.5% | +1.5% | -4.8% |
| Jun 9 | Citigroup | Maintains | Buy → Buy | — | $3.50 | $3.59 | +2.6% | +10.3% | -7.5% | -6.4% | +3.6% | -2.6% |
| Dec 21 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.13 | $4.00 | -43.9% | -50.9% | +9.7% | +8.6% | -2.2% | -0.5% |
| Dec 21 | Citigroup | Maintains | Buy → Buy | — | $7.13 | $4.00 | -43.9% | -50.9% | +9.7% | +8.6% | -2.2% | -0.5% |
| Apr 28 | Citigroup | Maintains | Buy → Buy | — | $14.85 | $14.13 | -4.8% | -6.2% | -10.2% | +0.5% | -0.6% | -4.0% |
| Mar 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.07 | $12.00 | -0.6% | +3.7% | -4.3% | -2.3% | +5.3% | -5.8% |
| Mar 12 | Citigroup | Maintains | Buy → Buy | — | $12.07 | $12.00 | -0.6% | +3.7% | -4.3% | -2.3% | +5.3% | -5.8% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.59 | $13.00 | +3.3% | -2.8% | -2.0% | -2.8% | +1.5% | +7.4% |
| Dec 16 | Berenberg | Maintains | Buy → Buy | — | $6.89 | $7.19 | +4.4% | +5.8% | +3.3% | +0.0% | +8.0% | -7.6% |
| Oct 30 | Jefferies | Maintains | Buy → Buy | — | $6.31 | $6.96 | +10.3% | +5.9% | -2.2% | +1.8% | +2.1% | +2.4% |
| Oct 16 | BTIG | Maintains | Buy → Buy | — | $6.86 | $7.33 | +6.9% | +18.1% | -1.9% | -4.7% | -6.3% | +6.9% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $6.89 | $6.91 | +0.3% | -4.1% | +1.7% | +0.3% | -1.8% | +4.2% |
| May 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.96 | $3.50 | +18.2% | +13.2% | +6.0% | +5.6% | +20.0% | -6.7% |
| Dec 4 | Citigroup | Maintains | Buy → Buy | — | $9.26 | $9.56 | +3.2% | +8.4% | -1.9% | -6.3% | +1.1% | +1.7% |
| Sep 26 | Stifel | Maintains | Buy → Buy | — | $9.90 | $12.35 | +24.7% | +34.8% | +7.5% | -3.8% | -5.4% | +1.8% |
| Sep 13 | Janney Capital | Maintains | Buy → Buy | — | $8.00 | $8.20 | +2.5% | -2.5% | +0.6% | -2.5% | +2.6% | +2.5% |
| Jan 26 | Seaport Global | Maintains | Buy → Buy | — | $7.25 | $7.40 | +2.1% | +2.8% | +2.0% | -0.3% | -1.3% | +0.3% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.20 | $6.90 | +11.3% | +3.2% | -2.3% | +1.6% | -1.6% | +0.8% |
| Sep 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.65 | $6.35 | +12.4% | +12.4% | +70.1% | -17.6% | +2.2% | -20.3% |
| Sep 26 | H.C. Wainwright | Maintains | Buy → Buy | — | $7.45 | $7.60 | +2.0% | +3.4% | +0.6% | -3.4% | +0.4% | +4.0% |
| Jul 1 | Stifel | Maintains | Buy → Buy | — | $5.69 | $5.87 | +3.2% | +6.3% | +1.5% | +3.1% | +5.4% | +1.9% |
| Sep 8 | TD Cowen | Maintains | Outperform → Outperform | — | $7.08 | $7.50 | +5.9% | +1.1% | -2.0% | -2.8% | +2.3% | -2.0% |
| Jul 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.76 | $8.34 | +7.5% | +7.1% | +2.3% | -1.5% | +1.3% | -6.5% |
| May 27 | Janney Capital | Maintains | Buy → Buy | — | $6.87 | $7.05 | +2.6% | +8.7% | +0.3% | -0.5% | +1.6% | +0.4% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $10.61 | $10.75 | +1.3% | +0.3% | -2.2% | +3.3% | -5.9% | +0.6% |
| Jan 26 | Laidlaw & Co. | Maintains | Buy → Buy | — | $8.86 | $9.44 | +6.5% | +11.3% | +11.3% | +5.7% | +2.2% | +2.2% |
| Dec 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $7.26 | $7.64 | +5.2% | +4.0% | -2.1% | -2.7% | +8.5% | -1.2% |
| Jun 19 | Aegis Capital | Maintains | Buy → Buy | — | $6.69 | $7.65 | +14.3% | +12.3% | -7.5% | +3.6% | -7.6% | +0.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Brady Todd C | President and CEO | Buy | 250,000 | $1.67 | $418K | 1,721,298 | +6.75% | +2.92% |
8-K · 5.02
!!! Very High
Aldeyra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 10
8-K · 7.01
! Medium
Aldeyra Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aldeyra Therapeutics disclosed updated clinical trial data and FDA feedback on its reproxalap dry eye disease treatment, providing transparency on efficacy endpoints and regulatory progress toward potential market approval.
May 1
8-K · 5.02
!!! Very High
Aldeyra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Aldeyra Therapeutics' board member Martin J. Joyce will not seek re-election, representing a leadership transition that investors should monitor for potential strategic implications.
Apr 20
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary describes only technical XBRL metadata and form structure rather than actual company events or financial disclosures that would impact stock valuations.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Aldeyra's dry eye disease drug failed FDA approval due to inconsistent efficacy data, eliminating a key pipeline asset and likely pressuring the stock significantly given the clinical setback.
Mar 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 1,314,064 | $7M | Reduced | Dec 2025 |
| 2 | Aqr Capital Management Llc | 2,829,875 | $5M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,363,742 | $4M | New | Mar 2026 |
| 4 | D.e. Shaw & Co | 1,403,990 | $2M | Reduced | Mar 2026 |
| 5 | Millennium Management | 995,243 | $2M | Added | Mar 2026 |
| 6 | Ardsley Advisory Partners Lp | 950,000 | $2M | Reduced | Mar 2026 |
| 7 | Jane Street Group, Llc | 303,852 | $2M | Added | Dec 2025 |
| 8 | Renaissance Technologies Llc | 863,187 | $1M | Added | Mar 2026 |
| 9 | Acadian Asset Management Llc | 858,288 | $1M | Reduced | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 807,778 | $1M | New | Mar 2026 |
| 11 | Propel Bio Management, Llc | 730,606 | $1M | New | Mar 2026 |
| 12 | Ubs Group Ag | 537,569 | $908K | Added | Mar 2026 |
| 13 | Northern Trust Corp | 374,812 | $633K | Reduced | Mar 2026 |
| 14 | Hrt Financial Lp | 286,444 | $484K | New | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 278,442 | $471K | Added | Mar 2026 |
| 16 | Woodstock Corp | 266,756 | $451K | — | Mar 2026 |
| 17 | Ieq Capital, Llc | 266,518 | $450K | Added | Mar 2026 |
| 18 | Citadel Advisors Llc | 266,340 | $450K | New | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 223,537 | $378K | Reduced | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 215,332 | $364K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$110.4M
Enterprise Value
$38.1M
P/E (TTM)
—
Forward P/E
26.14x
PEG Ratio
0.23x
P/B
2.48x
P/S
—
P/FCF
0.00x
EV/EBITDA
—
Shares Out
60.1M
Financials (TTM)
Revenue
$0
Net Income
-$27.4M
EBITDA
-$25.2M
Free Cash Flow
-$33.35T
Op Cash Flow
-$33.35T
EPS Basic
$-0.56
EPS Diluted
$-0.46
EPS Forward
$0.07
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$72.1M
Total Liab.
$27.8M
Total Equity
$44.3M
Cash
$70.0M
LT Debt
$0
Book Value/Sh
$0.74
Debt/Equity
0.35x
Current Ratio
2.58
Quick Ratio
2.58
Returns & Growth
ROE
-76.5%
ROA
-47.0%
ROIC
-59.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+40.4%
Price Returns
2W
+5.4%
1M
+15.1%
3M
-67.9%
6M
-68.1%
12M
-18.6%
Technicals
52W High
$6.17
52W Low
$1.07
50d MA
$1.71
200d MA
$3.90
RSI (14)
52.20
ATR (14)
$0.15
Beta
1.33
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.67
High
$12.00
Low
$7.00
Median
$10.00
Data updated apr 24, 2026 5:11pm
· Source: financialmodelingprep.com